−3.34USD
−81.828MUSD
29.567M
About Biomea Fusion, Inc.
Sector
CEO
Thomas Butler
Headquarters
Redwood City
Website
Employees (FY)
83
Founded
2017
ISIN
US09077A1060
Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic disorders, such as diabetes. It offers its lead product candidate, BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. The company was founded by Thomas Butler and Ramses Erdtmann in August 2017 and is headquartered in Redwood City, CA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
